CTLA-4 inhibitor and PD-1 inhibitor (PD-1/PD-L1 inhibitor) have strong antitumour activities in different tumours including melanoma, non-small-cell lung cancer and kidney cancer [22, 23]. Here, CTLA4 is linked to non-small cell lung carcinoma.